SCHEMBL857553

SCHEMBL857553

CS(=O)(=O)c1ccc2[c]ncnc2c1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.34
IDE P14735 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TNNI3K Q59H18 2/20 0.34
PIP4K2C Q8TBX8 1/20 0.34
CBFB Q13951 1/20 0.33
ENPP2 Q13822 1/20 0.33
NPBWR1 P48145 1/20 0.33
LMNA P02545 1/20 0.33
PDE5A O76074 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
SCD O00767 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL855586 0.87 NPBWR1 (0.36) G6PDIDESMN1; SMN2TNNI3KPIP4K2C
SCHEMBL857163 0.72 PARP1 (0.32)
SCHEMBL27468180 0.71 GLP1R (0.34)
SCHEMBL855664 0.71 NR4A2 (0.38) LMNA
SCHEMBL855315 0.69 EGFR (0.49) SMN1; SMN2LMNA
SCHEMBL23903922 0.67 OGA (0.46) G6PDIDESMN1; SMN2CBFBENPP2
SCHEMBL856173 0.67 PDE4A (0.46) PIP4K2CLMNAPDE5APTGS1PTGS2
SCHEMBL27747790 0.66 GPR119 (0.42) PTGS1PTGS2
SCHEMBL856757 0.63 PDE4B (0.46) PIP4K2CLMNAPDE5APDE4B
SCHEMBL1266021 0.62 MMP12 (0.42) CBFBNPBWR1SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA G6PD 1838/4885IDE 2073/4885SMN1; SMN2 3705/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA G6PD 2119/4885IDE 2098/4885SMN1; SMN2 3818/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA G6PD 1745/4885IDE 1960/4885SMN1; SMN2 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.